Korea’s Celltrion Will Support Hospira On EU Infliximab Sales While Setting Sights On Japan
This article was originally published in PharmAsia News
Executive Summary
How Celltrion and Hospira will share the European market remains to be seen, but Celltrion says the partners will support each other in taking on J&J’s Remicade. The Korean company also files for approval of infliximab in Japan, setting up another potential battleground on biosimilars.